AnaptysBio, Inc. (ANAB) Gets FDA OK for Jemperli in MSI-H/dMMR Rectal Cancer
AnaptysBio (ANAB) announced FDA approval for GSK's Jemperli as the first immunotherapy for adults with stage II-III MSI-H/dMMR locally advanced rectal cancer. The approval, based on AZUR-1 data, shows 68% of participants had no detectable cancer after one year, with no recurrences reported after 2+ years of follow-up. GSK will present full data at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
Regulatory approval expands market size and could accelerate revenue, supporting a bullish outlook for ANAB.
Market read
First FDA approval for this indication; likely triggers immediate price reaction and sector interest.
What to watch
Reimbursement negotiations and competition from other MSI-H agents could temper revenue growth.
Background
AnaptysBio partners with GSK; Jemperli already approved for other MSI-H cancers, now extended to rectal cancer.
Ticker impact
FDA approval of Jemperli for MSI-H/dMMR rectal cancer expands AnaptysBio's royalty stream and market opportunity.
upside pressure as market incorporates expanded royalty potential.
Regulatory win is a primary, material event; AnaptysBio's collaboration with GSK means immediate royalty upside.
Market effects
Biotech sector may see increased focus on MSI-H/dMMR indications, boosting peers with similar pipelines.
U.S. biotech investors likely respond positively; European partners may see ancillary interest.
Adds to global oncology pipeline momentum, potentially influencing cross‑border collaborations.
Counterpoint
If Jemperli's uptake is slower than expected, royalty forecasts could be overstated, limiting upside.
Key entities
- companyAnaptysBio, Inc.
Biotech firm receiving FDA approval for Jemperli indication.
- companyGlaxoSmithKline (GSK)
Partner receiving FDA approval and paying royalties to AnaptysBio.